In IRI-AKI, treatment with SIRT1 activator SRT1720 restores the expression of PGC-1α in kidneys, leading to enhanced mitochondria biogenesis characterized by the increase of mitochondrial mass and ATP levels, and improved renal function [103]. The gene discussed is SIRT1; the disease is acute kidney injury.